>
>
US quantitative market assessment: novel therapy for infectious disease
Client Problems
-
A top 50 global pharma company wanted to know how they could reach $500M US peak sales for a Phase 2/3 drug treating latent tuberculosis (LTBI)
-
The company also sought advice on how to re-frame the large and ill-defined literature prevalence to a more realistically addressable universe of patients, as well as identifying ways to grow that market
What We Did
Primary qualitative market research with 6 MD specialties (n=30) and payers (n=20)
Primary quantitative market research (conjoint design) with physicians across 6 specialties (n=350), and payers (n=50)
Market, revenue forecast, TPP assessment, and business case (NPV) analysis
Our Results And Insight
-
We illuminated the current market segments
-
Quantified MD demand in light of various product profile scenarios
-
Conjoint analyses with MDs and payers prioritized the key obstacles to uptake…
-
…and provided actionable steps to overcome those obstacles
See other case studies
Market Research case studies >
Other Therapeutic Areas case studies >
Service Areas Details
Market Research (Quantitive & Qualitative Study, TPP testing, Market Forecast Research)
Therapeutic Areas Details
Other Therapeutic Areas (Infectious Disease, Tuberculosis)
Featured Consultants
